Objective-Blood vessel wall damage often results in the formation of a fibrin clot that traps inflammatory cells, including monocytes. The effect of clot formation and subsequent lysis on the expression of monocyte-derived genes involved in the development and progression of ischemic stroke and other vascular diseases, however, is unknown. Determine whether clot formation and lysis regulates the expression of human monocyte-derived genes that modulate vascular diseases. Approach and Results-We performed next-generation RNA sequencing on monocytes extracted from whole blood clots and using a purified plasma clot system. Numerous mRNAs were differentially expressed by monocytes embedded in clots compared with unclotted controls, and IL-8 (interleukin 8) and MCP-1 (monocyte chemoattractant protein-1) were among the upregulated transcripts in both models. Clotted plasma also increased expression of IL-8 and MCP-1, which far exceeded responses observed in lipopolysaccharide-stimulated monocytes. Upregulation of IL-8 and MCP-1 occurred in a thrombinindependent but fibrin-dependent manner. Fibrinolysis initiated shortly after plasma clot formation (ie, 1-2 hours) reduced the synthesis of IL-8 and MCP-1, whereas delayed fibrinolysis was far less effective. Consistent with these in vitro models, monocytes embedded in unresolved thrombi from patients undergoing thrombectomy stained positively for IL-8 and MCP-1. examined. Our results demonstrate that fibrinolysis significantly downregulates IL-8 and MCP-1 synthesis by monocytes, depending on when lysis was initiated. These findings have significant implications in ischemic stroke because timely administration of tPA after stroke dictates outcomes.
C oagulation contributes to the pathogenesis of many disease processes, including sepsis, myocardial infarction, and ischemic stroke. 1, 2 On vessel injury, blood is exposed to tissue factor, resulting in the formation of thrombin that stems blood loss by activating coagulation proteases and platelets. [3] [4] [5] Thrombin also induces the conversion of fibrinogen to fibrin, resulting in the formation of clots that seal wounds. 6, 7 When clots form, they trap numerous blood cells, including monocytes. Monocytes play an important role in bridging hemostasis and inflammation because they generate tissue factor and inflammatory cytokines in response to external stimuli. [8] [9] [10] Perhaps the most well-known stimulus of monocyte gene expression is lipopolysaccharide (LPS). 11, 12 However, LPS is not present in most clinical situations where clots form, and individual clotting factors, such as tissue factor, thrombin, 13, 14 and fibrin, [15] [16] [17] have variable and generally mild stimulatory effects on monocyte gene expression. This suggests that clots are ineffective triggers of gene expression by monocytes, but this assumption has not been rigorously tested. Accordingly, we determined whether intact clots alter gene expression patterns in monocytes using human models of whole blood and plasma clot formation. Our data demonstrate that clots induce marked changes in the monocyte transcriptome, including increased expression of IL-8 (interleukin-8) and MCP-1 (monocyte chemoattractant protein-1). Remarkably, these shifts were more intense than changes in gene expression induced by LPS.
After fibrin formation occurs under physiological conditions, tPA (tissue-type plasminogen activator) is generated and immediately begins breaking down the fibrin matrix. 18 Iatrogenic fibrinolysis is used as a therapeutic intervention in pathological thrombosis. 19, 20 In the setting of stroke, tPA is administered at high levels to quickly dissolve the clot and improve blood flow to ischemic brain. In either setting, the effect of fibrinolysis on cytokine expression has not been examined. Our results demonstrate that fibrinolysis significantly downregulates IL-8 and MCP-1 synthesis by monocytes, depending on when lysis was initiated. These findings have significant implications in ischemic stroke because timely administration of tPA after stroke dictates outcomes.
Materials and Methods
Materials and Methods is available in the online-only Data Supplement.
Results

Whole Blood Clots Trigger Inflammatory Gene Expression in Monocytes
To test whether clots trigger inflammatory gene expression, whole blood was clotted with recombinant tissue factor in the presence of calcium for 2 hours, and gene expression patterns were examined in purified monocytes. Isolated monocytes were mostly CD14 + C16 − (>90%), and this population did change significantly after whole blood clot formation ( Figure   I in the online-only Data Supplement). RNA-seq revealed that monocytes expressed over 10 000 transcripts and nearly 1000 were differentially expressed (ie, >4-fold) in clot-retrieved monocytes compared with baseline monocytes ( Figure 1A ). Among the differentially expressed transcripts were IL-8 and MCP-1, which were increased by >6-and 48-fold, respectively, in clot-retrieved monocytes ( Figure 1A and 1B) . Increased mRNA expression was confirmed by real-time polymerase chain reaction ( Figure II in the online-only Data Supplement) and was associated with elevated levels of IL-8 and MCP-1 protein, which accumulated in a time-dependent fashion ( Figure 1C ). In addition to IL-8 and MCP-1, 13 other proteins involved in inflammation were increased after whole blood clot formation, and mRNA for these genes correlated with their protein expression levels ( Figure III in the onlineonly Data Supplement). These cytokines were also expressed in thrombi extracted from patients ( Figure IV in the onlineonly Data Supplement), indicating that in vivo clot formation is also associated with the generation of inflammatory proteins.
Plasma Clot Formation Induces Inflammatory Gene Expression in Monocytes
Next we determined whether clotted plasma triggers gene expression in a manner similar to whole blood. For these studies, recombinant tissue factor was added to recalcified, cell-free plasma and allowed to clot before addition of purified autologous monocytes ( Figure V in monocytes embedded within clots compared with freshly isolated monocytes (baseline), unstimulated monocytes (untreated) that were left in suspension culture for equivalent time periods, or thrombin-stimulated monocytes (Figure 2A and B. Similarity matrices demonstrated that RNA patterns for freshly isolated, untreated and thrombin-stimulated, and clot-retrieved monocytes clustered in distinct nodes (Figure 2A and B). More than 1100 transcripts were differentially expressed by >4-fold between the clotted and control groups ( Figure 2C ). In addition, patterns of gene expression in monocytes isolated from whole blood and plasma clots were moderately correlated with one another ( Figure 
MCP-1 and IL-8 Expression Are Regulated at the Transcriptional Level
Protein for IL-8 and MCP-1 was markedly increased after 18 hours but not before then ( Figure 3A 
Fibrin Formation Is Required for Cytokine Synthesis
Results displayed in Figure 2E and 2F demonstrate that treatment of purified monocytes (ie, not in plasma) with low concentrations of thrombin (0.1 U/mL) did not have appreciable effects on IL-8 and MCP-1 mRNA or protein levels, and thrombin did not increase global protein synthesis ( Figure   IX in the online-only Data Supplement). We also found that increasing concentrations of purified thrombin had no appreciable effect on IL-8 or MCP-1 synthesis ( Figure 4A ). However, pretreatment of plasma with heparin, which blunts thrombin generation and, thereby, clot formation, significantly reduced IL-8 and MCP-1 synthesis ( Figure 4B ). The specific thrombin inhibitor lepirudin also reduced cytokine synthesis in a dose-dependent manner ( Figure 4C ). These studies indicated that thrombin generation, but not thrombin itself, is critical for clot-dependent cytokine production.
Because thrombin converts fibrinogen to fibrin, we determined whether mediators released into the clotted milieu or fibrin formation are required for cytokine synthesis. The addition of fibrin-free serum did not induce IL-8 or MCP-1 synthesis ( Figure 5A ), suggesting that fibrin formation is the primary instigator of these synthetic events. To examine this postulate in more detail, we added Gly-Pro-Arg-Pro to thrombin-treated plasma to see if inhibition of fibrin polymerization prevents MCP-1 and IL-8 synthesis. As shown in Figure 5B , the addition of Gly-Pro-Arg-Pro blocked IL-8 and MCP-1 synthesis. The concentration of Gly-Pro-Arg-Pro to inhibit fibrin formation had no effect on LPS-stimulated monocytes (Figure XII in the online-only Data Supplement). We also found that the addition of tissue factor and calcium to fibrinogen-deficient plasma did not induce a robust cytokine response as compared with the presence of fibrinogen ( Figure 5C ). In addition, tissue factor, alone, had little effect on cytokine production (Figure XIII in the online-only Data Supplement). Reintroduction of fibrinogen to fibrinogen-deficient plasma, however, triggered IL-8 and MCP-1 synthesis in a concentration-dependent manner ( Figure 5D ). When thrombin generation was blocked by the presence of heparin, but fibrin formation was allowed to proceed by the addition of batroxobin-a snake venom capable of cleaving fibrinogen-monocytes synthesized IL-8 and MCP-1 ( Figure 5E ). Fibrin stabilization through factor (F) XIII may play a critical role inducing monocyte-derived IL-8 and MCP-1. To address the role of FXIII, we formed plasma clots in the presence and absence of a specific FXIII inhibitor, T101. Plasma clots formed in the presence of T101 had reduced fibrin cross-linking but had no effect on cytokine production ( Figure XIV in the online-only Data Supplement). In addition, plasma clots were generated in the presence and absence of FXIII using FXIII-deficient plasma. In the absence of FXIII, we observed decreased fibrin crosslinking but no change in IL-8 and MCP-1 synthesis ( Figure  XIV in the online-only Data Supplement). We next examined whether purified fibrinogen and thrombin alone were sufficient to induce IL-8 and MCP-1 synthesis. Interestingly, purified fibrinogen and thrombin did not recapitulate the plasma system (Figure XV in the online-only Data Supplement). However, the addition of serum to purified fibrinogen and thrombin induced robust IL-8 and MCP-1 secretion. Taken together, these results indicate that fibrin formation in the setting of plasma induces inflammatory gene expression in monocytes.
Fibrinolysis Blunts Clot-Induced Cytokine Synthesis in a Time-Dependent Manner
Next we determined whether fibrinolysis (breakdown of the fibrin clot) affects clot-induced cytokine synthesis. Monocyte mRNA expression patterns were examined in plasma clots that were lysed with tPA 30 minutes after clot formation and the addition of monocytes. As shown in Figure 6A , mRNA expression patterns were markedly different in clot-retrieved monocytes compared with untreated monocytes, and these changes were blunted in the presence of tPA. Furthermore, patterns of gene expression in monocytes isolated from plasma clots and plasma clots plus tPA demonstrated a negative correlation with one another (R=0.807, Figure 5 . Fibrin formation induces the inflammatory response in monocytes. A, Purified, cell-free plasma clots were triggered with recombinant tissue factor and calcium. After 2 hours, serum was removed from the plasma clots by centrifuging the sample at 12 000g for 20 minutes. Monocytes were then incubated with plasma clots or in residual serum. B, Monocytes were embedded into plasma fibrin clots formed in the presence of Gly-Pro-Arg-Pro (GPRP), a fibrin polymerization inhibitor or vehicle (water). C, Monocytes were embedded in plasma clots that were generated from normal plasma or fibrinogen-deficient plasma. D, Monocytes were embedded in fibrinogendeficient plasma that was reconstituted with increasing concentrations of fibrinogen. E, Plasma fibrin clots were formed in the presence of heparin to prevent thrombin generation and in the presence or absence of batroxobin (1 U/mL), which generates fibrin in a thrombinindependent manner. As a control, monocytes were resuspended in M199 and stimulated with batroxobin. In all treatment conditions, cell-free supernatants were harvested after 18 hours, and IL-8 (interleukin-8) and MCP-1 (monocyte chemoattractant protein-1) levels were assessed. The bars in the panels represent the mean±SEM of 3 independent experiments for each group. The asterisk and hashtag indicates P>0.05 in clot samples versus their comparative controls. October 2017 P<0.001; Figure XVI in the online-only Data Supplement), demonstrating that the fibrinolysis significantly blunted inflammatory gene responses. Monocytes isolated from lysed samples had reduced expression of IL-8 and MCP-1 mRNA when compared with clot-retrieved monocytes ( Figure 6B ), and protein for these cytokines was similarly reduced ( Figure 6C ). Decreases in IL-8 and MCP-1 were time-dependent and not durable when tPAtreatment was delayed by >2 hours after addition of monocytes ( Figure 6D ). tPA treatment similarly reduced IL-8 and MCP-1 protein levels when it was administered to whole blood 1 hour after clots were formed ( Figure 6C ).
Discussion
Monocytes play prominent roles in driving coagulation and inflammation, in part, through de novo synthesis of thromboinflammatory proteins on stimulation. Here, we determined for the first time intact clots trigger robust, global expression of inflammatory genes in monocytes, including IL-8 and MCP-1. Thrombi extracted from patients demonstrated similar patterns of cytokine expression, suggesting that in vivo clot formation can also induce the generation of IL-8 and MCP-1 ( Figure IV in the online-only Data Supplement). The ability of the clot to activate multiple inflammatory cytokines RNA-seq analysis of monocytes derived from whole blood clots demonstrated robust differential gene expression compared with monocytes isolated immediately after whole blood was drawn. To further verify specific changes in the monocyte transcriptome because of plasma clot formation, we performed additional RNA-seq analysis from monocytes embedded in a purified plasma clot system. RNA-seq analysis revealed that monocytes embedded in plasma clots mounted a robust gene expression response, and differentially expressed mRNAs resembled observed changes in the more complex whole blood clot ( Figure The data indicate that generation of fibrin is essential for plasma clot-induced changes in gene expression. We first demonstrated using heparin, a clinically useful anticoagulant, a significant reduction in cytokine protein expression. To focus on the role of thrombin, we next used the direct thrombin inhibitor lepirudin, 21 which also blocked the production of cytokines. We did not observe IL-8 and MCP-1 synthesis when increasing concentrations of thrombin were introduced to purified monocytes in the absence of plasma, despite the fact that the higher doses used exceeded previously reported peak levels of thrombin generation. 22, 23 We also found that thrombin did not increase global protein synthesis by monocytes, and mRNA patterns in thrombin-stimulated monocytes clustered with mRNA expression in unstimulated monocytes. These results are similar to those produced by Nieuwenhuizen et al 13 who demonstrated that high concentrations of thrombin did not induce cytokine synthesis but contrast a report showing that thrombin regulates the expression of inflammatory mRNAs.
14 The reasons for these differences are not obvious but may be because of the techniques (RNA-sequencing versus microarray analysis) and the experimental milieus used. Others have used genetics models to examine the role of thrombin in regulating inflammation. For example, deletion of protease activator receptor 1, the major receptor for thrombin signaling, had no effect on macrophage cytokine synthesis. 24 Taken together, these findings indicate only a small role for thrombin in regulating these inflammatory responses.
Although thrombin did not directly modulate gene expression in purified, plasma-free monocytes, our data demonstrate that thrombin is still indirectly necessary for cytokine responses by acting on fibrinogen. Our data suggest that thrombin exerts its effect by inducing fibrin formation, which directly triggers gene expression pathways in monocytes. Indeed, pretreatment of plasma with the peptide Gly-Pro-Arg-Pro, which inhibits fibrin polymerization by blocking A:a interactions, significantly reduced cytokine synthesis. 25, 26 Likewise, fibrinogen-deficient plasma failed to support cytokine production, but reintroduction of fibrinogen to plasma restored clot formation and cytokine synthesis. Batroxobin, 27 which cleaves fibrinogen into fibrin independent of thrombin, also restored clot formation and supported IL-8 and MCP-1 production in heparinized plasma. These data demonstrate that fibrin formation elicits gene expression responses in monocytes. However, the absence of fibrinogen did not completely abolish cytokine formation ( Figure 5C ), and purified fibrin generated by thrombin was unable to induce IL-8 and MCP-1 synthesis ( Figure  XV in the online-only Data Supplement). These findings suggest that additional factors circulating in the plasma or generated during clot formation are necessary in addition to fibrin to induce robust cytokine response in monocytes. While the current study focused on the role of fibrin in the setting of plasma, additional studies are warranted to determine other critical factors important in regulating this response.
The exact mechanism by which fibrinogen/fibrin drive IL-8, MCP-1, and other inflammatory gene expression is not known. Previous studies have demonstrated that fibrin(ogen) is capable of inducing synthesis of IL-8, MCP-1, IL-6, IL-1β, and other cytokines in immune cells and vascular endothelial cell in vitro and in vivo. 24, [28] [29] [30] [31] The mechanism behind fibrinogen-or fibrin-driven cytokine responses was thought to be through TLR4 (toll-like receptor-4) on macrophages. 32, 33 However, inhibition of TLR4 34, 35 had no effect on cytokine production ( Figure XIX in the online-only Data Supplement), suggesting that ligation of TLR4 by fibrinogen is not the mechanism for induction of cytokine synthesis in our experiments. 29 In addition, these data indicate that low levels of LPS in clots are not responsible for increased IL-8 and MCP-1 synthesis. The generation of FXIIIa and its role in stabilizing fibrin through cross-linking may also play a role in driving the cytokine response in monocytes. Previous studies have demonstrated that FXIIIa is capable of binding to α v β 3 on monocytes and upregulating proliferation and migration while preventing apoptosis. 36 Using pharmacological inhibition and FXIII-deficient plasma, we observed minimal changes in IL-8 and MCP-1 synthesis ( Figure XIV in the online-only Data Supplement). Another possibility is CD11b/CD18, which binds fibrinogen/fibrin with high affinity through the c-terminal region of fibrinogen's gamma chain. 37 It has been shown that this site becomes exposed on conversion of fibrinogen to fibrin, 38, 39 and previous publications have shown that interactions of fibrin with CD11b/CD18 regulate NF-κB-dependent cytokine production. Interestingly, pharmacological inhibition of NF-κB blunts clot-induced synthesis of IL-8 and MCP-1 ( Figure XI in the online-only Data Supplement). However, an inhibitory antibody against CD11b blocked fibrinogen binding but had little effect on cytokine production ( Figure XX in the online-only Data Supplement). Additional studies using mice deficient in CD11b/CD18 are necessary to fully examine the role CD11b/CD18 in plasma clot-mediated IL-8 and MCP-1 synthesis because studies using CD11b/C18 knockout mice demonstrated that they are protected from cerebral ischemia reperfusion injury, 40 suggesting that interactions of fibrin with CD11b/CD18 may regulate inflammatory processes during stroke.
While the ability of fibrin to interact with vessels and cells is important in stemming blood loss, fibrin deposition and its prompt removal are necessary in wound repair. 41 The removal of fibrin from a thrombus is regulated by the generation of plasmin from its proform, plasminogen. Plasminogen binding to fibrin in conjunction with tPA results in plasmin generation and the subsequent degradation of the fibrin clot 18 ; therefore, a delicate balance is needed under physiological conditions between procoagulant and fibrinolytic processes to prevent bleeding or thrombosis and to ensure proper wound repair. Previous studies in plasminogendeficient mice have demonstrated exacerbated inflammatory diseases associated with arthritis, nerve damage, and osteoporosis. [42] [43] [44] [45] Genetic or pharmacological depletion of fibrinogen rescued the associated phenotype, suggesting that fibrin and its subsequent lysis modulates the disease process. 42, 44, 45 Additionally, Cole et al 46 demonstrated that plasminogen-deficient animals have elevated levels of IL-6. These studies, together with our findings, demonstrate that the balance between fibrin formation and lysis critically regulates IL-8, MCP-1, and other inflammatory cytokine production by monocytes.
As many as 795 000 individuals experience a new or recurrent stroke in the United States each year. 47 Intravenous fibrinolytic therapy involving the use of tPA for acute stroke is widely agreed on to be beneficial if administered within 3 to 4.5 hours of symptom onset. 48 This demonstrates that timely administration of tPA is necessary for maximal benefit to the patients. While fibrinolytics allow for reperfusion in the ischemic area, our data suggest an added benefit of timely fibrinolysis is modulation of cytokine production in the ischemic area. Specifically, addition of tPA to clots within 2 hours significantly reduces the synthesis of IL-8 and MCP-1. Increased inflammation is a hallmark finding in stroke, as evidenced by increased levels of IL-8, MCP-1, IL-1β, and other cytokines in the blood-which associate with poor outcomes. [49] [50] [51] While these studies suggest certain cytokines are important in regulating outcomes in stroke, they have not examined the role of fibrinolytic therapy in regulating cytokine expression after stroke. Our findings demonstrate for the first time and strongly suggest that the positive benefits of timely tPA administration in stroke is due, in part, to an attenuated inflammatory response.
